Boston Scientific received FDA 510(k) clearance for its SpyGlass DS Direct Visualization System. The system is cleared for use in the diagnosis and treatment of pancreatico-biliary disease.
Boston Scientific named Charles J. Dockendorff and Stephen P. MacMillan to its board of directors.
Boston Scientific Senior Vice President David A. Pierce sold 11,958 shares of Boston Scientific stock. The shares were sold at an average price of $16.46, for a total value of $196,828.
Exact Sciences stated a 3.8 percent gain, 1,018,354 shares, in short interest.
Exact Sciences reported its financial results for the fourth quarter of 2014 and full-year. The company reported $1.5 million in revenue for the fourth quarter, up from $1 million during the fourth quarter of 2013. Exact Sciences’ total revenues for the year were $1.8 million, down from $4.1 million in 2013.
A patient of Ronald Reagan UCLA Medical Center in Los Angeles filed a lawsuit against Olympus in regards to the recent carbapenem-resistant Enterobacteriaceae outbreak linked to contaminated duodenoscopes.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
AGA launches new award for CRC awareness month
GI societies, FDA to hold workshop on regulations, therapeutics advancements in GI ‘
Global endoscopy systems market to reach $6.1B by 2020
